ARWR
$57.02
Arrowhead Pharma
($3.37)
(5.58%)
ARWR
Earnings Whisper ®
N/A
1st Quarter December 2020
Consensus:  $0.46
Revenue:  N/A
Monday
Feb 22
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ARWR reports earnings?
Beat
Meet
Miss

Where is ARWR's stock price going from here?
Up
Flat
Down
Stock chart of ARWR
Analysts
Summary of analysts' recommendations for ARWR
Score
Grade
Pivots
Resistance
$63.56
$61.87
$59.44

$57.75

Support
$55.32
$53.63
$51.20
Tweet
Growth
Description
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Peers
Alexion PharmaceuticalsIncyteExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex